Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion

John Marra, Gina Zini, Nicoletta Pelliccioni, Eugenio Galli, Federica SORA, Silvia Bellesi, Marcello Viscovo, Ilaria Pansini, Alessandro Corrente, Giuseppe Leone, Stefan Hohaus, Simona Sica, Patrizia Chiusolo

Blood (2025) 146 (Supplement 1): 7690.

https://doi.org/10.1182/blood-2025-7690

Published: 2025

Journal Articles

Which inflammation matters? distinct risk signatures before CAR-T cell therapy and the role of inflamix

Ilaria Pansini, Eugenio Galli, Alessandro Corrente, Patrizia Chiusolo, Marcello Viscovo, Giuseppe Leone, Silvia Bellesi, Nicola Piccirillo, Stefan Hohaus, Federica SORA, Simona Sica

Blood (2025) 146 (Supplement 1): 7625.

https://doi.org/10.1182/blood-2025-7625

Published: 2025

Journal Articles

Btkis and DRC show a reduction of infections and need of hospitalization towards BR and other chemo-immunotherapies in waldenstrom macroglobulinemia.

Blood (2025) 146 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2025-1833

Published: 2025

Journal Articles

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007

Marco Ladetto, David Lavie, Tae Min Kim, Eva Gonzalez Barca, Ewa Paszkiewicz-Kozik, Stefan Hohaus, Caterina Patti, Jan Zaucha, Ömür Gökmen Sevindik, Yulia Volchek, Raul Cordoba, Guillermo Rodríguez Garcia, Sebastian Giebel, Benedetta Puccini, Tadeusz Robak, Siruo Wang, Puja Patel, Rushdia Yusuf, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 5516.

https://doi.org/10.1182/blood-2025-5516

Published: 2025

Journal Articles

Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study

Blood (2025) 146 (Supplement 1): 5402.

https://doi.org/10.1182/blood-2025-5402

Published: 2025

Journal Articles

Very low risk for secondary malignancies with btkis in Waldenström macroglobulinemia: A retrospective real-world multicenter study.

Blood (2025) 146 (Supplement 1): 5390.

https://doi.org/10.1182/blood-2025-5390

Published: 2025

Journal Articles

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FIL_RI-CHOP

Blood (2025) 146 (Supplement 1): 55.

https://doi.org/10.1182/blood-2025-55

Published: 2025

Journal Articles

An immune desert phenotype underlies therapy resistance in LBCL through distinct microenvironment-related miRNA profiles

Giulia Regazzo, Giulia Vari, Francesco Marchesi, Francesca Palombi, Andrea Sacconi, Giulia Orlandi, Mariangela Novello, Elena Papa, Martina Tomassi, Francesco Bertoni, Elena Maiolo, Andrea Mengarelli, Stefan Hohaus, Maria Rizzo

Blood (2025) 146 (Supplement 1): 5303.

https://doi.org/10.1182/blood-2025-5303

Published: 2025

Journal Articles

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

Maria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, Matin Salehi, Federico Jauk, Gabriela Forestieri, Simone Bocchetta, Deborah Piffaretti, Riccardo Moia, Vanessa Cristaldi, Martina di Trani, Georgia Alice Galimberti, Katia Pini, Valeria Spina, Claudia Giordano, Adalgisa Condoluci, Ilaria Romano, Salvatore Annunziata, Fabrizio Bergesio, Renzo Boldorini, Eugenio Borsatti, Pietro Bulian, Eleonora Calabretta, Stephane Chauvie, Francesco Corrado, Stefania Crisci, Marco Cuzzocrea, Rosaria De Filippi, Bernhard Gerber, Michał Kurlapski, Luigi Maria Larocca, Elisabetta Merlo, Andrea Rinaldi, Marcello Rodari, Grzegorz Romanowicz, Gian Mauro Sacchetti, Anastasios Stathis, Georg Stüssi, Ilaria Zangrilli, Antonello Pinto, Luca Mazzucchelli, Valter Gattei, Jan Maciej Zaucha, Armando Santoro, Stefan Hohaus, Franco Cavalli, Alexandar Tzankov, Carmelo Carlo-Stella, Gianluca Gaidano, Luca Ceriani, Emanuele Zucca, Davide Rossi

Blood (2025) 146 (10): 1207–1224.

https://doi.org/10.1182/blood.2024027355

Published: 2025

Includes: Supplemental data

Journal Articles

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2024) 144 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2024-203004

Published: 2024

Journal Articles

Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma

Maria Cristina Pirosa, Matin Salehi, Alessio Bruscaggin, Lodovico Terzi Di Bergamo, Federico Jauk, Gabriela Forestieri, Simone Bocchetta, Deborah Piffaretti, Riccardo Moia, Vanessa Cristaldi, Martina di Trani, Georgia Alice Galimberti, Katia Pini, Valeria Spina, Claudia Giordano, Adalgisa Condoluci, Salvatore Annunziata, Fabrizio Bergesio, Renzo Boldorini, Eugenio Borsatti, Pietro Bulian, Stephane Chauvie, Marco Cuzzocrea, Bernhard Gerber, Michal Kurlapski, Luigi Maria Larocca, Andrea Rinaldi, Marcello Rodari, Grzegorz Romanowicz, Gian Mauro Sacchetti, Anastasios Stathis, Georg Stüssi, Ilaria Zangrilli, Eleonora Calabretta, Francesco Corrado, Antonello Pinto, Luca Mazzucchelli, Valter Gattei, Jan Maciej Zaucha, Armando Santoro, Stefan Hohaus, Franco Cavalli, Emanuele Zucca, Gianluca Gaidano, Carmelo Carlo-Stella, Alexandar Tzankov, Luca Ceriani, Davide Rossi

Blood (2024) 144 (Supplement 1): 2960.

https://doi.org/10.1182/blood-2024-208175

Published: 2024

Journal Articles

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 578.

https://doi.org/10.1182/blood-2024-200271

Published: 2024

Journal Articles

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2024-198076

Published: 2024

Journal Articles

Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study

Blood (2024) 144 (Supplement 1): 3013.

https://doi.org/10.1182/blood-2024-200111

Published: 2024

Journal Articles

A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna

Matin Salehi, Maria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi Di Bergamo, Federico Jauk, Gabriela Forestieri, Simone Bocchetta, Deborah Piffaretti, Riccardo Moia, Vanessa Cristaldi, Martina Di Trani, Georgia Alice Galimberti, Katia Pini, Valeria Spina, Claudia Giordano, Adalgisa Condoluci, Salvatore Annunziata, Fabrizio Bergesio, Renzo Boldorini, Eugenio Borsatti, Pietro Bulian, Stephane Chauvie, Marco Cuzzocrea, Bernhard Gerber, Michal Kurlapski, Luigi Maria Larocca, Andrea Rinaldi, Marcello Rodari, Grzegorz Romanowicz, Gian Mauro Sacchetti, Anastasios Stathis, Georg Stüssi, Ilaria Zangrilli, Eleonora Calabretta, Francesco Corrado, Antonello Pinto, Luca Mazzucchelli, Valter Gattei, Jan Maciej Zaucha, Armando Santoro, Stefan Hohaus, Franco Cavalli, Emanuele Zucca, Gianluca Gaidano, Carmelo Carlo-Stella, Alexandar Tzankov, Luca Ceriani, Davide Rossi

Blood (2024) 144 (Supplement 1): 854.

https://doi.org/10.1182/blood-2024-207234

Published: 2024

Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Blood (2024) 144 (9): 1001–1009.

https://doi.org/10.1182/blood.2023023525

Published: 2024

Includes: Supplemental data

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Ranjana H. Advani, Abraham Avigdor, Anna Maria Sureda Balari, David Lavie, Stefan Hohaus, Jan M. Zaucha, Vu Minh Hua, Vittorio Ruggero Zilioli, Raimundo Gazitua, Muhit Ozcan, Amos Odeleye-Ajakaye, Nishitha Reddy, Patricia Marinello, Jane N. Winter

Blood (2023) 142 (Supplement 1): 3068.

https://doi.org/10.1182/blood-2023-181171

Published: 2023

Journal Articles

Blood-Brain Barrier and Neuronal Damage during Icans in Patients Treated with Anti-CD19 CAR-T Cells

Eugenio Galli, Anna Modoni, Luca Battistini, Monica Rossi, Gisella Guerrera, Ilaria Pansini, Stefan Hohaus, Andrea Bacigalupo, Simona Sica, Patrizia Chiusolo, Ferderica Sorà

Blood (2023) 142 (Supplement 1): 2128.

https://doi.org/10.1182/blood-2023-179226

Published: 2023

Journal Articles

Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?

Blood (2023) 142 (Supplement 1): 1667.

https://doi.org/10.1182/blood-2023-179460

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion

Which inflammation matters? distinct risk signatures before CAR-T cell therapy and the role of inflamix

Btkis and DRC show a reduction of infections and need of hospitalization towards BR and other chemo-immunotherapies in waldenstrom macroglobulinemia.

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007

Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study

Very low risk for secondary malignancies with btkis in Waldenström macroglobulinemia: A retrospective real-world multicenter study.

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FIL_RI-CHOP

An immune desert phenotype underlies therapy resistance in LBCL through distinct microenvironment-related miRNA profiles

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study

A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Blood-Brain Barrier and Neuronal Damage during Icans in Patients Treated with Anti-CD19 CAR-T Cells

Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only